VIVUS investors could barely bask in the glow of Qsymia's approval before they found themselves in the crosshairs of short-sellers. Well-known blog Citron Research published a piece attacking the strength of VIVUS' patents, and although the blog authors acknowledge they are not patent lawyers, a steep sell-off ensued. What does this mean for VIVUS and its competitors? Watch and find out.
Obesity drugs aren't the only game-changing invention. The Motley Fool has just released a free report on mobile named "The Next Trillion-Dollar Revolution" that details a hidden component play inside mobile phones that also is a leader in the exploding Chinese market. Inside the report, we not only describe why the mobile revolution will dwarf any other technology revolution seen before it, but we also name the company at the forefront of the trend. Hundreds of thousands have requested access to previous reports, and you can access this new report today by clicking here -- it's free.
David Williamson owns shares of Amarin, but he holds no other position in any other company mentioned. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.